trending Market Intelligence /marketintelligence/en/news-insights/trending/tbvdrknalst95npzduhslq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Mallinckrodt secures additional $26M in US funding to develop burn therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Mallinckrodt secures additional $26M in US funding to develop burn therapy

Mallinckrodt PLC said it will receive an additional $26 million from the U.S. government to study its burn therapy StrataGraft in children.

The additional award from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, pushes total government funding for the therapy to $86 million. The U.K.'s Mallinckrodt can secure up to an additional $160 million for StrataGraft, which is being developed by its subsidiary Stratatech Corp. as a medical countermeasure for large-scale burn incidents.

StrataGraft is a human skin substitute that is yet to be approved by the U.S. Food and Drug Administration. The regulator has designated StrataGraft as a regenerative medicine advanced therapy, which will allow for an accelerated review process.

StrataGraft, which is designed to work like natural skin, is being studied in a phase 3 trial for adults.

BARDA is a division of the U.S. Department of Health and Human Services tasked with the procuring and developing countermeasures against bioterrorism, including chemical, nuclear and radiological threats, as well as pandemic influenza and emerging diseases.